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Additive prognostic value of red 
cell distribution width over late 
gadolinium enhancement on cMR 
in patients with non-ischemic 
dilated cardiomyopathy
Jeong-eun Yi1, Hye-Jeong Lee2, Young Jin Kim2, Yookyung Kim3, Boyoung Joung  4 & 
Junbeom park5 ✉
elevated red cell distribution width (RDW) and late gadolinium enhancement on cardiac magnetic 
resonance (LGe-cMR) are both poor prognostic factors. this study examined the relationship between 
RDW and LGe-cMR characteristics in patients with non-ischemic dilated cardiomyopathy (nicM), and 
investigated whether the additive prognostic value of RDW as an integrative systemic factor over LGe-
CMR exists or not. A total of consecutive 378 patients who underwent CMR at two general hospitals 
in South Korea were retrospectively analyzed. the primary endpoint was a composite of all-cause 
death, hospitalizations due to worsening heart failure and major arrhythmic events. During a mean 
follow-up period of 40.8 months, 151 (39.9%) patients experienced primary endpoints. The RDW value 
was significantly higher in patients with LGE than in those without LGE (13.7 ± 1.5% vs. 13.3 ± 1.4%, 
p = 0.034), but it was not associated with the extent or distribution patterns of the LGE. Addition 
of RDW into the model with clinical risk factors and LGE-CMR characteristics led to a significant 
improvement in the prediction of worse outcomes (χ2 increased from 73 to 82; p = 0.023). RDW could 
provide incremental predictive value for adverse clinical events beyond LGe-cMR data in nicM patients.
Red cell distribution width (RDW) is a hematological parameter reflecting the degree of variation in the size of 
circulating erythrocytes and is used to differentiate the etiology of anemia1. Recently, the RDW has emerged as a 
poor prognostic marker among patients with various cardiovascular diseases, including coronary artery disease 
(CAD), peripheral artery disease (PAD), atrial fibrillation (AF), and heart failure (HF)2. Numerous studies have 
reported that an elevated RDW not only is a strong independent predictor of adverse outcomes in patients with 
HF3, but also predicts the risk of developing HF in the general population4. However, the exact mechanism link-
ing an elevated RDW with a poor prognosis, particularly in patients with HF, is poorly understood5. To the best 
of our knowledge, there is a paucity of data on the clinical significance of the RDW in the risk stratification of 
non-ischemic dilated cardiomyopathy (NICM) for adverse cardiac events.
Cardiac magnetic resonance (CMR) imaging with gadolinium is a non-invasive imaging modality to accu-
rately identify and quantify myocardial fibrosis known as a well-established risk factor of adverse cardiac events 
in patients with NICM6. Previous studies have demonstrated that the presence, extent, and distribution pattern 
of late gadolinium enhancement on CMR (LGE-CMR) can provide incremental prognostic information beyond 
the left ventricular ejection fraction (LVEF) in this population6,7. In some reports, although the presence of LGE 
had localized effects, it was associated with chronic inflammation that has been implicated in the pathogenesis 
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of fibrosis8–10. However, LGE itself does not always mean the pathologic fibrosis or scarring of the myocardium11, 
and it is also unknown whether the progression and increase in the LGE could exactly reflect the underlying 
systemic inflammation. Moreover, the assessment of the LGE-CMR has limited ability to detect diffuse interstitial 
fibrosis, which is another subtype of myocardial fibrosis commonly found in patients with NICM12.
This study aimed to examine the association between RDW and LGE-CMR in patients with NICM, and fur-
ther assessed the incremental value of RDW as a systemic marker beyond the localized LGE-CMR in the predic-
tion of worse outcomes.
Results
Baseline characteristics. A total of 378 patients were included in the analysis, and the mean age was 
55 ± 15 years and 237 (62.7%) were males. During a mean follow-up of 40.8 ± 36.1 months, the primary end-
point occurred in 151 (39.9%) patients. Among them, there were 112 (29.6%) of death, 61 (16.1%) of worsening 
HF, and 51 (13.5%) of major arrhythmic events. The baseline clinical characteristics are summarized in Table 1. 
Compared to the patients without events, subjects with events tended to be older and current smokers, and had 
a significantly lower body mass index (BMI) and diastolic blood pressure (BP) level. Patients with events had a 
significantly higher RDW level (13.9 ± 1.5% vs. 13.4 ± 1.4%, p = 0.001), along with lower hemoglobin, hemat-
ocrit, platelet (PLT) count, estimated glomerular filtration rate calculated using the Modification of Diet in Renal 
Disease formula (eGFRMDRD), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL) levels than 
those without events. Although the proportion of diabetes mellitus (DM) was higher in the subjects with events 
than in those without events, the hemoglobin A1c level was similar between them. There were no significant dif-
ferences in the other co-morbidities and N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive 
protein (CRP) levels between the two groups.
Table 2 shows LGE-CMR characteristics. The mean LVEF was 24.1 ± 8.9%. Patients with events had greater 
biventricular end-diastolic and end-systolic volume indices compared to those without events, however, the LV 
and right ventricular (RV) EF were similar between the two groups. LGE was present in 258 (68.3%) patients 
and the mean LGE extent was 7.3 ± 11.8%. LGE was more frequently observed in patients with events compared 
to those without events (82.8% vs. 58.6%, p < 0.0001), and the extent of the LGE was greater in patients with 
events (11.4 ± 14.8% vs. 4.5 ± 8.2%, p < 0.0001). The LGE distribution patterns were identified as midwall in 166 
(43.9%), patchy in 123 (32.5%), transmural in 29 (7.7%), subendocardial in 16 (4.2%), and subepicardial in 9 
(2.4%) patients, respectively. Midwall (55.6% vs. 36.1%, p < 0.0001), subepicardial (4.6% vs. 0.9%, p = 0.033), and 
transmural (11.9% vs. 4.8%, p = 0.011) patterns were more frequently observed in patients with events.
Relationship between RDW and LGe-cMR characteristics. Patients with LGE had a higher RDW 
level than those without LGE (13.7 ± 1.5% vs. 13.3 ± 1.4%, p = 0.034) (Fig. 1). However, RDW was not correlated 
with the extent of LGE (p = 0.779) and there were no significant differences in the RDW level across the distribu-
tion pattern of LGE (p = 0.164).
clinical outcomes. The Kaplan-Meier survival curves in the groups of patients categorized by the RDW 
and LGE-CMR characteristics (presence or absence and extent of the LGE) are shown in Fig. 2. Patients with 
>13.3% had a lower event-free survival rate than those with ≤13.3% (Log-rank, p < 0.0001) (Fig. 2A). In both 
patients with and without LGE, the possibility of experiencing a composite end point was significantly increased 
in patients with a higher RDW level than in those with a lower RDW level (Log-rank, p = 0.014 and p = 0.001, 
respectively) (Fig. 2B). Moreover, patients with a higher RDW level exhibited a significantly lower event-free sur-
vival rate than those with a lower RDW level in the subjects with a greater extent of the LGE (>3.4%) (Log-rank, 
p = 0.004), as well as in those with a smaller extent of the LGE (≤3.4%) (Log-rank, p = 0.005) (Fig. 2C). Patients 
with a higher RDW level and the presence or greater extent of the LGE had the lowest survival among the groups 
(overall Log-rank, p < 0.0001, respectively). On the other hand, the event-free survival rates of the higher RDW 
group with the absence or a smaller extent of the LGE were similar to those in the lower RDW group with the 
presence (Log-rank, p = 0.852) or greater extent (Log-rank, p = 0.925) of the LGE.
Table 3 demonstrates the Cox regression analyses for the primary endpoint of adverse events. A univariate 
Cox analysis showed significant associations between adverse events and the RDW (per 1% increase) (unadjusted 
hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.11–1.33, p < 0.0001), BMI, diastolic BP, current smoker, 
hemoglobin, Ln PLT count, Ln NT-proBNP, eGFRMDRD < .60(mL/min/1 73m )2 , use of digoxin, LVEDVI, presence and 
extent of the LGE, midwall and transmural distributions of the LGE. In multivariate analysis, the RDW (per 1% 
increase) (adjusted HR 1.17, 95% CI 1.04–1.33, p = 0.010) and presence (adjusted HR 3.41, 95% CI 1.82–6.41, 
p < 0.0001) and extent (per 1% increase) (adjusted HR 1.02, 95% CI 1.01–1.04, p = 0.010) of the LGE, along with 
an older age, lower diastolic BP, and being a current smoker were associated with a poor clinical outcome.
The receiver operating characteristics (ROC) analysis was performed to assess the combined value for RDW 
and LGE extent in predicting adverse clinical events. The area under the curve (AUC) for RDW, LGE extent and 
the combination of RDW and LGE extent were 0.618 (95% CI, 0.56– 0.68), 0.678 (95% CI, 0.62– 0.73) and 0.740 
(95% CI, 0.69– 0.79), respectively (Fig. 3). Furthermore, the addition of the RDW into the model with the clinical 
risk factors and LGE-CMR data significantly improved the overall χ2 score over the model with the clinical risk 
factors plus LGE-CMR data alone (global χ2 73 vs.82, p = 0.023) (Fig. 4).
Discussion
The major findings of our study conducted in patients with NICM were: 1) RDW level was significantly higher in 
patients with LGE than in those without LGE, but it was not associated with the extent and distribution pattern of 
the LGE; 2) an elevated RDW predicted adverse clinical events independent of LGE-CMR characteristics, and it 
could provide an incremental predictive value for a poor outcome over a combination of the clinical risk factors 
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and LGE-CMR. This was the first study to describe the relationship between the RDW and LGE-CMR, and to 
assess the additive prognostic value of the RDW over LGE-CMR data in patients with NICM. The clinical impli-
cation of RDW in patients with HF was first reported by Felker et al.13. In this large prospective study of 2,679 
symptomatic chronic HF patients, higher RDW levels were associated with cardiovascular death or HF hospitali-
zations and all-cause mortality. The association between an elevated RDW and adverse outcomes was also found 
in patients with acute HF14, and the meta-analysis has shown a significant prognostic value of the RDW for HF 
patients3. However, most data were short-term follow-up studies including patients with HF of various etiologies. 
Recently, although Wasilewski et al. found a significant association between high RDW and long-term mortality 
in a subgroup of patients with non-ischemic LV systolic dysfunction, coronary angiogram to rule out ischemic 
Variables Total (n = 378)




(n = 227) p Value*
Age (years) 55 ± 15 56 ± 15 54 ± 15 0.056
Male, n (%) 237 (62.7) 94 (62.3) 143 (63.0) 0.884
Body mass index (kg/m2) 24.7 ± 4.4 24.1 ± 4.3 25.2 ± 4.5 0.034
Systolic BP (mmHg) 119 ± 19 117 ± 19 120 ± 19 0.239
Diastolic BP (mmHg) 75 ± 13 73 ± 13 76 ± 14 0.016
Heart rate (bpm) 81 ± 16 81 ± 15 81 ± 17 0.830
NYHA class ≥ 3, n (%) 195 (51.6) 78 (51.7) 117 (51.5) 0.983
Current smoker, n (%) 96 (25.5) 46 (30.7) 50 (22.0) 0.059
Diabetes mellitus, n (%) 107 (28.3) 54 (35.8) 53 (23.3) 0.009
Hypertension, n (%) 172 (45.5) 73 (48.3) 99 (43.6) 0.366
AF or AFL, n (%) 78 (20.6) 26 (19.2) 49 (21.6) 0.575
QRS duration (msec) 109 ± 25 111 ± 25 108 ± 25 0.445
QTc duration (msec) 467 ± 41 469 ± 44 466 ± 39 0.538
Medications
  ACEi or ARB, n (%) 349 (92.3) 137 (90.7) 212 (93.4) 0.341
  Beta-blocker, n (%) 284 (75.1) 102 (67.5) 182 (80.2) 0.005
  Loop diuretics, n (%) 210 (82.0) 130 (86.1) 180 (79.3) 0.092
  Spironolactone, n (%) 246 (65.1) 109 (72.2) 137 (60.4) 0.018
  Digoxin, n (%) 126 (33.4) 71 (47.0) 55 (24.3) <0.0001
  Amiodarone, n (%) 19 (5.0) 12 (7.9) 7 (3.1) 0.034
  Antiplatelet, n (%) 180 (47.6) 76 (50.3) 104 (45.8) 0.389
  Anticoagulant, n (%) 95 (25.1) 37 (24.5) 58 (25.6) 0.818
  Statin, n (%) 122 (32.3) 52 (34.4) 70 (30.8) 0.463
WBC count (x103/µL) 6930 (5740–8180) 6630 (5510–8000) 7100 (5900–8220) 0.160
Hemoglobin (g/dL) 13.8 ± 2.1 13.3 ± 2.1 14.2 ± 2.0 <0.0001
Hematocrit (%) 41.0 ± 6.0 39.4 ± 6.2 42.1 ± 5.6 <0.0001
Mean corpuscular volume (fL) 90.2 ± 5.1 89.7 ± 4.9 90.4 ± 5.2 0.684
Red cell distribution width (%) 13.6 ± 1.5 13.9 ± 1.5 13.4 ± 1.4 0.001
PLT count (x103/L) 235 (186–290) 217 (175–273) 241 (198–294) 0.004
Fasting glucose (mg/dL) 113 ± 41 112 ± 32 113 ± 47 0.751
HbA1c (%) 6.6 ± 1.4 6.7 ± 1.3 6.5 ± 1.5 0.496
Blood urea nitrogen (mg/dL) 16.1 (13.0–21.5) 17.7 (13.4–24.2) 15.4 (13.0–20.1) 0.004
Creatinine (mg/dL) 1.0 (0.8–1.2) 1.0 (0.9–1.3) 1.0 (0.8–1.2) 0.008
eGFRMDRD (mL/min/1.73m2) 76.0 (63.1–91.3) 72.6 (56.7–89.5) 78.0 (66.1–92.8) 0.004
Total cholesterol (mg/dL) 169 ± 38 161 ± 38 174 ± 39 0.002
Triglyceride (mg/dL) 123 ± 73 122 ± 78 124 ± 69 0.887
HDL cholesterol (mg/dL) 43 ± 14 42 ± 15 44 ± 14 0.157
LDL cholesterol (mg/dL) 107 ± 32 101 ± 29 110 ± 33 0.013
NT-proBNP (pg/mL) 2620 (1008–5746) 2952 (1102–6764) 2521 (862–5010) 0.212
C-reactive protein (mg/dL) 2.2 ± 2.4 2.3 ± 2.3 2.2 ± 2.5 0.755
Table 1. Baseline characteristics. *Comparisons between patients with and without events. HF, heart failure; 
BP, blood pressure; NYHA, New York Heart Association; AF, atrial fibrillation; AFL, atrial flutter; ACEi, 
angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; WBC, white blood cell; 
PLT, platelet; HbA1c, hemoglobin A1c; eGFRMDRD, estimated glomerular filtration rate calculated using the 
Modification of Diet in Renal Disease formula; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
NT-proBNP, N-terminal pro-brain natriuretic peptide.
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etiology of HF with significant CAD was not performed in all participants15. The present study was also clinically 
meaningful in that it was the first study to evaluate the prognostic significance of RDW in a relatively large num-
ber of NICM patients who were completely confirmed by coronary angiogram or computed tomography.
HF is a complex clinical syndrome characterized by a reduced ability of the ventricle to fill or eject blood, 
which can be caused by many different conditions leading to any structural or functional cardiac abnormali-
ties16. Interestingly, various factors causing hematopoietic dysfunction and anisocytosis such as inflammation, 
oxidative stress, nutritional deficiency, renal failure and aging also have been involved in the development or 
worsening of HF2,5. Özülkü et al. reported an independent negative association between the RDW level and 
coronary flow reserve in patients with idiopathic dilated CMP17. The authors described that higher RDW levels 
reflect a chronic inflammatory state, resulting in impaired coronary microcirculation and LV systolic dysfunction. 
In our study of NICM patients, there was a negative relationship between the RDW level and LVEF (r = –0.132, 
p = 0.017). Moreover, patients with LGE had a significantly higher level of the RDW, as well as higher levels of the 
CRP (3.3 ± 3.9 mg/dL vs. 2.1 ± 2.8 mg/dL, p = 0.008) and NT-proBNP (3245 [1393, 6523] pg/mL vs. 1769 [436, 
4040] pg/mL, p < 0.0001) compared to those without LGE (Supplementary Figure S1). Given the pathogenesis of 
Variables Total (n = 378)







LVEF (%) 24.1 ± 8.9 23.8 ± 8.8 24.7 ± 9.0 0.166
LVEDVI (ml/m2) 154.7 (128.3–193.2)
166.5 (133.7–
202.6) 143.9 (117.4–180.2) 0.001
LVESVI (ml/m2) 127.3 ± 54.5 140.2 ± 60.1 117.0 ± 47.4 0.001
RVEF (%) 33.7 ± 15.6 33.6 ± 15.4 33.7 ± 15.7 0.941
RVEDVI (ml/m2) 98.9 ± 41.4 108.3 ± 48.5 91.9 ± 33.9 0.007
RVESVI (ml/m2) 68.8 ± 38.0 75.6 ± 45.4 63.8 ± 30.8 0.035
Presence of LGE 258 (68.3) 125 (82.8) 133 (58.6) <0.0001
Extent of LGE (%) 7.3 ± 11.8 11.4 ± 14.8 4.5 ± 8.2 <0.0001
Patterns of LGE
   Subendocardial, n (%) 16 (4.2) 8 (5.3) 8 (2.5) 0.401
   Midwall, n (%) 166 (43.9) 84 (55.6) 82 (36.1) <0.0001
   Subepicardial, n (%) 9 (2.4) 7 (4.6) 2 (0.9) 0.033
   Transmural, n (%) 29 (7.7) 18 (11.9) 11 (4.8) 0.011
   Patchy, n (%) 123 (32.5) 54 (35.8) 69 (30.4) 0.276
Table 2. CMR characteristics. *Comparisons between patients with and without events. CMR, cardiac 
magnetic resonance; HF, heart failure; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end 
diastolic volume index; LVESVI, left ventricular end systolic volume index; RVEF, right ventricular ejection 
fraction; RVEDVI, right ventricular end diastolic volume index; RVESVI, right ventricular end systolic volume 
index; LGE, late gadolinium enhancement.
Figure 1. Comparison of the mean level of RDW between the patients with and without LGE RDW, red cell 
distribution width; LGE, late gadolinium enhancement.
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myocardial fibrosis following chronic inflammation, a high RDW seems to be associated with the inflammatory 
process of NICM10.
Several studies have shown a significant increase in the inflammatory markers and its relationship with a poor 
prognosis in NICM patients18–21. Vergaro G et al. reported a significant association between galectin-3 and myo-
cardial fibrosis assessed by the LGE20. Furthermore, a recently published study demonstrated that growth differ-
entiation factor-15, a cytokine involved in inflammation and fibrosis, was linked to an adverse cardiac remodeling 
Figure 2. Kaplan-Meier survival curves in the groups of patients categorized by the RDW (≤13.3% vs. 
>13.3%) (A), RDW (≤13.3% vs. >13.3%) and presence or absence of LGE (B) or the extent of the LGE (≤3.4% 
vs. >3.4%) (C). RDW, red cell distribution width; LGE, late gadolinium enhancement.
Variables
Univariate analysis Multivariate analysis
Unadjusted HR 
(95% CI) p Value
Adjusted HR 
(95% CI) p Value
RDW (%) 1.22 (1.11 – 1.33) <0.0001 1.17 (1.04 – 1.33) 0.010
Age (years) 1.01 (0.99 – 1.02) 0.086 1.03 (1.01 – 1.04) 0.001
Male 1.07 (0.77 – 1.49) 0.671
BMI (kg/m2) 0.96 (0.92 – 0.99) 0.038
Diastolic BP (mmHg) 0.98 (0.97 – 0.99) 0.003 0.97 (0.96 – 0.99) 0.001
NYHA class 1.07 (0.86 – 1.32) 0.526
Diabetes mellitus 1.23 (0.88 – 1.72) 0.220
Hypertension 1.09 (0.79 – 1.50) 0.606
Current smoker 1.45 (1.03 – 2.06) 0.035 1.74 (1.11–2.70) 0.015
Hemoglobin (g/dL) 0.85 (0.79–0.92) <0.0001
Ln PLT count 0.48 (0.31–0.73) 0.001
Ln NT-proBNP 1.20 (1.05–1.38) 0.008
eGFRMDRD < 60 (mL/min/1.73m2) 1.73 (1.22–2.46) 0.002
Use of digoxin 1.80 (1.31–2.48) <0.0001
LVEF (%) 0.98 (0.96–1.00) 0.072
LVEDVI (mL) 1.01 (1.00–1.01) <0.0001
Presence of LGE 2.65 (1.74–4.05) <0.0001 3.41 (1.82–6.41) <0.0001
LGE extent (%) 1.03 (1.02–1.04) <0.0001 1.02 (1.01–1.04) 0.010
Pattern of LGE
No LGE 1 (reference)
Subendocardial 1.51 (0.73–3.10) 0.268
Midwall 2.04 (1.44–2.87) <0.0001
Subepicardial 1.70 (0.77–3.77) 0.190
Transmural 2.86 (1.66–4.93) <0.0001
Patchy 1.12 (0.80–1.58) 0.501
Table 3. Cox regression analyses for prediction of adverse clinical events. RDW, red cell distribution width; 
BMI, body mass index; HR, hazard ratio; CI, confidence interval; BP, blood pressure; NYHA, New York 
Heart Association; Ln PLT, log-transformed platelet; Ln NT-proBNP, log-transformed N-terminal pro-brain 
natriuretic peptide; eGFRMDRD, estimated glomerular filtration rate calculated using the Modification of Diet in 
Renal Disease formula; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end-diastolic volume 
index; LGE, late gadolinium enhancement.
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and worsening functional capacity21. As mentioned above, the RDW may also be a strong surrogate marker of 
inflammation, which is one of the most important pathologic processes in HF. However, it still remains contro-
versial whether an elevated RDW is just an epiphenomenon of an underlying biological or metabolic imbalance, 
or a real risk factor. Hemorheologic alterations of RBCs in conditions of high anisocytosis contribute to the 
inadequate myocardial perfusion, and the abnormal erythrocytes can directly behave as an active player in the 
pathogenesis of myocardial remodeling and fibrosis22. Allen LA et al. reported that not only inflammatory stress 
but also impaired iron mobilization could be a potential mechanism for the unfavorable prognostic effect of an 
elevated RDW23. In addition, an elevated RDW has been shown to have a significant association with poor CD34 
(+) stem cell mobilization24, and some clinical trials have demonstrated the beneficial effects of stem cell therapy 
in NICM patients25. In our study, RDW was not correlated with the CRP level (p = 0.779), but it had a signifi-
cant positive correlation with the NT-proBNP level (r = 0.383, p < 0.0001). Further, we found an independent 
association between an elevated RDW and an adverse outcome, and revealed an additive prognostic value of the 
RDW over the LGE-CMR characteristics. These findings suggested that the aforementioned hemorheological 
Figure 3. ROC curve analysis of RDW, LGE extent and the combination of RDW and LGE extent for predicting 
adverse clinical events. ROC, receiver operating characteristics; RDW, red cell distribution width; LGE, late 
gadolinium enhancement.
Figure 4. Incremental value of RDW for the prediction of adverse clinical events. Changes in the global χ2 
were compared to assess the additive prognostic value of RDW when added to the prediction model of clinical 
risk factors and LGE-CMR data. RDW, red cell distribution width; LGE, late gadolinium enhancement; CMR, 
cardiac magnetic resonance. Clinical risk factors; age, male, BMI, diastolic BP, NYHA class ≥ 3, DM, HTN, 
current smoker, hemoglobin, Ln NT-proBNP, eGFRMDRD < 60. LGE-CMR data; LVEF and presence, extent, and 
pattern of LGE.
7Scientific RepoRtS |         (2020) 10:9212  | https://doi.org/10.1038/s41598-020-66198-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
alterations, besides inflammation, may play an important role in the adverse prognostic impact of the RDW. Since 
the RDW reflects inflammation, as well as the hematopoietic activity affecting the progression of cardiovascular 
disease2, the RDW could be a reliable prognostic indicator in NICM patients.
Our study had several inherent limitations due to its retrospective design with a potential selection bias and 
limitations on the data acquisition. Although longitudinal RDW variations have been also associated with a poor 
prognosis and the association was even stronger than that for the baseline RDW26–28, a serial assessment of RDW 
was not available in our study. Moreover, we did not analyze the hemorheological parameters known to be well 
correlated with the RDW level, such as the RBC deformability or aggregation index and whole blood viscosity. 
Also, more sensitive and specific markers for inflammation than the CRP, and their relationships with the RDW 
were not investigated. Interestingly, our study population showed a significantly higher prevalence of LGE than 
those in a previously reported data29. Several studies have identified myocardial perfusion abnormalities and 
its association with myocardial fibrosis in patients with DCM, and described that microvascular dysfunction 
may play a role in the pathogenesis of DCM30–32. Microvascular dysfunction is well known to be associated with 
endothelial dysfunction linked to systemic inflammation33. Considering clinical characteristics of our study pop-
ulation having more atherosclerotic risk factors compared to prior studies, high prevalence of LGE in our study 
may suggest the presence of microvascular dysfunction. Unfortunately, we could not perform the additional 
functional studies to assess myocardial perfusion or coronary flow reserve due to retrospective design. In addi-
tion, our study population showed a high prevalence of patchy LGE, particularly at right ventricular insertion 
point (RVIP-LGE) that is generally considered to be nonspecific in patients with hypertrophic cardiomyopathy34. 
However, its clinical implication in other medical conditions still remains unclear, and in a recently published 
our study including 360 NICM patients, we found that patients with RVIP-LGE had a worse prognosis than 
those with absence of LGE35. Although tissue characteristics of RVIP-LGE was not confirmed by endomyocardial 
biopsy in this study, the image quality was checked, and the potential pitfalls and artifacts mimicking myocardial 
scar were also excluded by two experienced radiologists.
Finally, the identification and quantification of interstitial fibrosis using a novel imaging technique, such as 
T1 mapping or extracellular volume (ECV) estimates were not applicable and the serial change in the LGE-CMR 
characteristics during the follow-up was not assessed.
conclusion
Among patients with NICM, RDW level was significantly higher in subjects with LGE than in those without LGE. 
An elevated RDW was an independent predictor of adverse clinical outcomes, and we also found its additive 
prognostic value over LGE-CMR characteristics. The RDW could be an integrative prognostic marker represent-
ing both multiple pathologic factors and hemorheological alterations. A combined assessment of the RDW and 
LGE-CMR data may improve the risk stratification in NICM patients.
Methods
Study population. A total of 465 consecutive patients with newly diagnosed NICM who underwent CMR 
with gadolinium between May 2003 and February 2018 at two tertiary hospitals in South Korea were retrospec-
tively enrolled. All patients underwent CMR just after the diagnosis of NICM based on a detailed history and 
clinical evaluation, including a 12-lead electrocardiogram (ECG), echocardiography, and coronary angiogram 
or coronary CT. NICM was defined in accordance with the World Health Organization/International Society 
and Federation of Cardiology’s guidelines as follows: (1) presence of symptoms or signs of HF according to the 
Framingham criteria; (2) a reduced LVEF (<50%) without regional wall motion abnormalities; (3) an increased 
LV end-diastolic dimension (LVEDD > 55 mm); (4) no prior history of a myocardial infraction or revasculariza-
tion; and (5) absence of significant CAD on the coronary angiogram or coronary CT (>50% luminal narrowing 
of one or more coronary artery)36. Patients with medical conditions that could increase the plasma RDW levels, 
such as hematological diseases or a malignancy, chronic obstructive pulmonary disease, inflammatory bowel 
diseases, and severe arthritis were excluded. We also excluded subjects with acute myocarditis, significant valvu-
lar heart diseases (≥moderate degree), hypertrophic cardiomyopathy, and infiltrative cardiomyopathy or other 
specific cardiomyopathies, structural heart diseases, and prior cardiac surgery. Finally, 378 patients were identi-
fied as the study population. The study protocol conformed to the principles of the Declaration of Helsinki and 
was approved by the local ethics committee (EUMC 2017-09-019-004). The study protocol was approved by the 
Institutional Review Boards of two general hospitals, Ewha Womans University Mokdong Hospital and Severance 
Cardiovascular Hospital. All of the data were fully anonymized prior to access and informed consent was waived 
due to the retrospective nature of this study.
Blood sampling. All laboratory data, including the routine blood chemistry and hematologic parameters 
such as the hemoglobin, hematocrit, mean corpuscular volume (MCV), and RDW, were obtained within 3 days 
of the CMR. The RDW was measured as part of the automated complete blood count using the Advia 2120i auto-
mated analyzer (Siemens Healthcare Diagnostics, Deerfield, IL, USA).
cMR acquisition. All CMR imaging studies were performed on a 1.5-T scanner (Intera Achieva; Phillips 
Medical Systems, Best, The Netherlands or Phillips Healthcare, Andover, MA, USA) with a phase array cardiac 
coil at both centers. The CMR image acquisition has been reported previously37. ECG-gated cine images were 
acquired using a balanced steady-state free precession sequence with the following parameters: TR [repetition 
time]/TE [echo time], 3.4/1.7 ms; flip angle, 50°; field of view, 360 × 360 mm; matrix, 256 × 256 mm; slice thick-
ness, 8 mm; 25 frames per cardiac cycle; average number of signals, 1; and short axis planes encompassing the 
entire LV without a slice gap. Delayed enhancement images were acquired 10 minutes after infusing intravenous 
gadolinium-DTPA (0.2 mmol/kg; gadoterate dimeglumine; Dotarem, Geurbet) at 2 mL/s using a T1-weighted 
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2-dimensional gradient echo inversion recovery sequence with the following scanning parameters: TR/TE, 
5.3/1.6 ms; flip angle, 15°; field of view, 360 × 360 mm; matrix, 512 × 512 mm; slice thickness, 8 mm; average 
number of signals, 2; no interslice gap. The inversion time (T1) was individually optimized to nullify the signal of 
normal myocardium using a dedicated T1 determining sequence38.
cMR data analysis. All CMR images were reviewed using a dedicated software program (CMR42, Circle 
Cardiovascular Imaging, Calgary, Alberta, Canada) by the consensus of two experienced radiologists blinded to 
the patient clinical data and outcomes37. The LGE was visually assessed using a modified 16-segment model of 
the LV39, and the patterns of LGE were classified either as subendocardial, midwall, subepicardial, transmural, or 
patchy (Supplementary Figure S2)40. The LGE volume was quantified from a short-axis stack of images using a full 
width at half maximum (FWHM) technique, and the regional of interest was drawn in the area of the maximum 
signal intensity of a visible LGE for the FWHM threshold. The myocardial and LGE volumes were estimated from 
the sum of each area for each slice, multiplied by the slice thickness. The extent of the LGE was expressed as a 
percentage of the LGE volume, which was calculated by dividing the LGE volume by the myocardial volume, with 
a quotient multiplied by 100. The LGE analysis was performed twice by two independent expert readers blinded 
to all the patient details37. The inter-observer agreement between the two readers with respect to the presence or 
absence of an LGE was substantial (kappa value = 0.827, p < 0.005). The intra-observer variability of the LGE 
quantification for the coefficient of variation (CV) and intra-class correlation coefficient (ICC) were 12.5% and 
0.99 (95% confidence interval [CI] 0.97–0.99), respectively.
endpoints. After the baseline clinical and CMR data collection were completed, all medical records of all 
patients were reviewed in detail for the purposes of obtaining additional follow-up data. The primary end-
point was a composite of all-cause death, hospitalizations due to worsening HF and major arrhythmic events. 
We defined hospitalizations for HF as the first readmission with worsening signs or symptoms of HF requiring 
additional treatment for at least one of the following: (1) intravenous therapy (e.g. diuretics, vasodilators, and 
inotropes); (2) implementation of mechanical circulatory support or surgical intervention; and (3) use of ultrafil-
tration, hemofiltration, or dialysis. Major arrhythmic events included sustained ventricular tachycardia, ventricu-
lar fibrillation, appropriate implantable cardioverter defibrillator interventions, and sudden cardiac death (SCD). 
The cause and date of the death were confirmed using the information from the National Population Registry of 
Korea National Statistical Office, together with all available medical records at the time of the death. SCD was 
defined as an unexpected death from a cardiac cause occurring within 1 h of the symptom onset, or nocturnal 
death without any prior history of worsening symptoms.
Statistical analysis. Continuous variables were presented as the mean ± standard deviation (SD) or 
median (interquartile range, [IQR]) and were compared using independent t-tests or the Mann-Whitney test. 
Categorical variables were described as the n (%) and were compared using χ2 or Fisher’s exact tests. The asso-
ciation between the RDW and characteristics of the LGE were analyzed using a Spearman’s correlation coeffi-
cient and Kruskal-Wallis H test, as appropriate. Differences in the adverse event-free survival curves between the 
RDW (≤or > the median of 13.3%) and LGE (presence or absence of an LGE and ≤ or > the median of the LGE 
extent, 3.4%) groups were compared using a log-rank test. To investigate the independent association between 
the RDW and composite end point, a multivariate Cox regression analysis with a forward selection method was 
performed using covariates identified as significant in the univariate analysis (p < 0.05), as well as established 
risk factors for adverse cardiac events, including the characteristics of the LGE-CMR. The HRs for the prediction 
of the end points with 95% CIs were calculated. A ROC curve analysis was performed to assess the combined 
predictive value of RDW and the extent of LGE. The incremental predictive value of the RDW for the composite 
end point was assessed in the three different predictive models by comparing the global χ2 score of each model 
using ANOVA F tests. The baseline model consisted of clinical risk factors (age, male, BMI, diastolic BP, New 
York Heart Association [NYHA] class ≥3, DM, HTN, current smoker, hemoglobin, Ln NT-proBNP, and eGFRM-
DRD < 60). Additional models were compromised of the clinical risk factors plus the LGE-CMR data (LVEF and 
presence, extent, and pattern of LGE), or clinical risk factors and LGE-CMR data plus the RDW. All statistical 
analyses were conducted using software package SPSS 18.0 (SPSS Inc., Chicago, Illinois, USA) and P values <0.05 
were considered statistically significant.
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